Indian Heart Journal, 2015 Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. Aims: The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice.
Soumitra Kumar +2 more
exaly +5 more sources
Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats [PDF]
Research in Pharmaceutical SciencesBackground and purpose: Non-alcoholic fatty liver disease (NAFLD) is the most common liver-related metabolic disorder worldwide, affecting approximately 25% of the global population.
Elham Khoshbakht +4 more
doaj +2 more sources
Effect of Saroglitazar on Glycemic Status: A Meta-analysis. [PDF]
CureusThis systematic review and meta-analysis were conducted to assess the glycemic effect of saroglitazar in patients with type 2 diabetes or prediabetes and dyslipidemia.PubMed and Google Scholar databases were searched for randomized controlled trials and observational studies till December 2023.
Selvarajan S +7 more
europepmc +3 more sources
JGH Open, 2023 Background and Aim Saroglitazar, a dual PPAR α/γ agonist, is useful in management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of saroglitazar in NAFLD patients with or without diabetes including compensated cirrhosis ...
Sujit Chaudhuri
exaly +2 more sources
Saroglitazar Ameliorates Pulmonary Fibrosis Progression in Mice by Suppressing NF-κB Activation and Attenuating Macrophage M1 Polarization [PDF]
MedicinaBackground and Objectives: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with limited therapeutic options.
Yawen Zhang +3 more
doaj +2 more sources
IHJ Cardiovascular Case Reports (CVCR), 2017 This is a case report of 78 years old lady with uncontrolled type 2 diabetes and dyslipidemia. Patient was also suffering from impaired renal function with serum creatinine of 1.7 mg/dL.
Amitesh Kumar Chatterjee
exaly +3 more sources
Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real‐World Assessment of Liver and Metabolic Health [PDF]
Endocrinology, Diabetes & MetabolismBackground Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) is a significant health concern and is commonly associated with conditions such as dyslipidemia, insulin resistance, and increased risk of cardiovascular disease.
Mukulesh Gupta +4 more
doaj +2 more sources
From ‘Make in India’ to ‘Made in India’: The saroglitazar story
Indian Heart Journal, 2015 Indian pharmaceutical industry is successfully following the ‘make in India’ theme, much before it became a buzz word in governance. India has dominated themanufacturing of generic and bio-similar drugs. A few of the Indian companies have made anti-tubercular, anti-retroviral and anti-cancer drugs available to the vast majority of the world population ...
Sivasubramanian Ramakrishnan, MD, DM, FACC
doaj +3 more sources
Saroglitazar Mitigated Cyclophosphamide-Induced Testicular Injury: Crosstalk Between Oxidative Stress, Inflammation and Apoptosis [PDF]
PharmaceuticalsBackground: Cyclophosphamide (CYC) is an effective chemotherapeutic agent and immunosuppressant drug. Former research showed that CYC induces testicular toxicity through oxidative stress, inflammation and apoptosis.
Bandar H. Alanazi +2 more
doaj +2 more sources
Perspectives of Indian Gastroenterologists and Hepatologists on Nonalcoholic Fatty Liver Disease Diagnosis and Management: Insights From the Nationwide Web-Based Cross-Sectional DRIVE Survey [PDF]
Interactive Journal of Medical ResearchBackgroundNonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), represent an increasing clinical and public health burden in India. Despite their high prevalence, there are limited
Anil Arora +8 more
doaj +2 more sources